Quoin Pharmaceuticals Ltd
QNRX8.570USD
-1.080-11.19%
Handelsschluss 11/06, 16:00（ET）Kurse um 15 Minuten verzögert
176.42MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Quoin Pharmaceuticals Ltd Unternehmen
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Quoin Pharmaceuticals Ltd Informationen
BörsenkürzelQNRX
Name des UnternehmensQuoin Pharmaceuticals Ltd
IPO-datumNov 01, 1989
CEODr. Michael Myers, Ph.D.
Anzahl der mitarbeiter3
WertpapierartDepository Receipt
GeschäftsjahresendeNov 01
Addresse23 Hata'as Street
StadtKFAR SABA
BörseNASDAQ Capital Market Consolidated
LandIsrael
Postleitzahl44425
Telefon97299741444
Websitehttps://quoinpharma.com/
BörsenkürzelQNRX
IPO-datumNov 01, 1989
CEODr. Michael Myers, Ph.D.
Führungskräfte von Quoin Pharmaceuticals Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
440.00
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Mr. Yali Sheffi
Mr. Yali Sheffi
Independent External Director
Independent External Director
--
--
Mr. Guy Sapir
Mr. Guy Sapir
Internal Auditor
Internal Auditor
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
440.00
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, Sep 14
Aktualisiert: Sun, Sep 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Myers (Michael)
2.85%
Carter (Denise P)
2.85%
Langer (Dennis H)
2.51%
Dunn (Gordon)
0.72%
Culverwell (Anthony James)
0.47%
Andere
90.59%
Aktionäre
Aktionäre
Anteil
Myers (Michael)
2.85%
Carter (Denise P)
2.85%
Langer (Dennis H)
2.51%
Dunn (Gordon)
0.72%
Culverwell (Anthony James)
0.47%
Andere
90.59%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
9.48%
Investment Advisor
0.35%
Investment Advisor/Hedge Fund
0.05%
Research Firm
0.03%
Andere
90.09%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
28
2.58K
0.43%
-52.65K
2025Q2
34
51.05K
8.68%
-35.06K
2025Q1
35
78.22K
9.34%
-7.90K
2024Q4
33
2.93M
35.77%
+2.56M
2024Q3
29
288.95K
5.54%
-93.09K
2024Q2
30
301.96K
12.37%
-13.30K
2024Q1
28
276.13K
11.96%
+132.88K
2023Q4
28
104.03K
10.54%
-33.36K
2023Q3
27
83.72K
8.48%
+6.49K
2023Q2
28
91.62K
18.66%
+37.20K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Myers (Michael)
17.22K
0.08%
--
--
Jul 16, 2025
Carter (Denise P)
17.22K
0.08%
-1.00
-0.01%
Jul 16, 2025
Langer (Dennis H)
1.00
0%
-1.00
-50.00%
Jul 16, 2025
Dunn (Gordon)
4.32K
0.02%
--
--
Jul 16, 2025
Culverwell (Anthony James)
2.87K
0.01%
--
--
Jul 16, 2025
Rhumbline Advisers Ltd. Partnership
1.24K
0.01%
+49.00
+4.11%
Jun 30, 2025
Raymond James Financial Services Advisors, Inc.
717.00
0%
-1.00
-0.14%
Jun 30, 2025
Lawlor (Sally Bridget)
440.00
0%
+440.00
--
Aug 18, 2025
GAMMA Investing LLC
278.00
0%
+38.00
+15.83%
Sep 30, 2025
Morgan Stanley & Co. LLC
206.00
0%
+193.00
+1484.62%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Mar 26, 2025
Merger
20→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jul 29, 2022
Merger
12.5→1
Datum
Art
Verhältnis
Mar 26, 2025
Merger
20→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
Sep 23, 2021
Merger
4→1
Mehr Anzeigen
